In the context of cancer treatment, it was found that a combination of BCL-xL inhibitors together with MEK inhibitors could be efficient against KRAS mutant cancer models [61], highlighting cross-talk between the MAPK and the mitochondrion-dependent apoptosis pathways. This evidence concerns the gene BCL2L1 and cancer.